ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Daiichi Sankyo Co., Ltd.

Business Summary

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2023 JPYUSD
Gross Profit914,953M6,751.55M
Operating income102,162M753.86M
Income before tax126,873M936.21M
Net income109,188M805.71M
Diluted EPS56.910.42
Dividends Per Share300.22
Total Assets2,508.88B18,851.07M
Total liabilities1,063.03B7,987.30M
Total equity1,445.85B10,863.73M
Operating cash flow114,514M845.01M
Currency in JPYCurrency in USD

Historical Data

 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 929,717M 981,793M 962,516M 1,044.89B 1,278.47B
Gross Profit 565,112M 638,587M 624,227M 682,090M 914,953M
Operating income 90,461M 118,028M 80,179M 82,462M 102,162M
Income before tax 85,831M 141,164M 73,956M 73,387M 126,873M
Net income 93,410M 129,074M 75,957M 66,972M 109,188M
EBITDA 136,630M 170,639M 137,561M 150,181M 169,951M
Diluted EPS 47.95 66.26 39.11 34.90 56.91
Dividends Per Share 23.33 23.33 26.99 27 30
Total Assets 2,088.05B 2,105.61B 2,085.17B 2,221.40B 2,508.88B
Total liabilities 838,343M 791,549M 807,030M 864,865M 1,063.03B
Total equity 1,249.64B 1,305.80B 1,272.05B 1,350.87B 1,445.85B
Operating cash flow 92,033M 196,601M 192,207M 139,226M 114,514M
 Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Revenue 8,383.78M 9,029.99M 9,075.42M 9,298.45M 9,434.04M
Gross Profit 5,095.93M 5,873.37M 5,885.74M 6,069.89M 6,751.55M
Operating income 815.73M 1,085.55M 755.99M 733.82M 753.86M
Income before tax 773.98M 1,298.34M 697.32M 653.06M 936.21M
Net income 842.33M 1,187.15M 716.18M 595.98M 805.71M
EBITDA 1,232.07M 1,569.44M 1,297.04M 1,336.45M 1,254.08M
Diluted EPS 0.43 0.60 0.36 0.31 0.42
Dividends Per Share 0.21 0.21 0.25 0.24 0.22
Total Assets 18,864.80M 19,504.59M 18,870.38M 18,301.97M 18,851.07M
Total liabilities 7,574.13M 7,332.21M 7,303.43M 7,125.56M 7,987.30M
Total equity 11,290.07M 12,095.86M 11,511.79M 11,129.73M 10,863.73M
Operating cash flow 829.91M 1,808.22M 1,812.29M 1,238.96M 845.01M

Valuation Measures

Mar 2023
Operating margin7.99%
Profit margin8.54%

Key executives

  • President, CEO & Representative Director: Sunao Manabe
  • CFO, Director & General Manager-Administration: Hiroyuki Okuzawa
  • Director & Chief Information Officer: Masahiko Ohtsuki
  • Global Director-Research & Development: Ken Takeshita
  • General Manager-Research & Development: Wataru Takasaki


  • Nomura Asset Management Co., Ltd. (5.1%)
  • Nippon Life Insurance Co. (4.4%)
  • Capital Research & Management Co. (World Investors) (4.3%)
  • Asset Management One Co., Ltd. (3.2%)
  • BlackRock Fund Advisors (2.7%)
  • The Vanguard Group, Inc. (2.5%)
  • Wellington Management Co. LLP (2.5%)
  • Nikko Asset Management Co., Ltd. (2.0%)
  • Daiwa Asset Management Co. Ltd. (2.0%)
  • Mizuho Bank Pension Fund (1.9%)

Contact Details

  • Website:
  • Address: Daiichi Sankyo Head Office Bldg, A&B, 3-5-1 Nihonbashi-honcho, Tokyo, 103-8426, Japan
  • Phone: +81.3.6225.1111

Related Companies

  • Daiichi Sankyo Chemical Pharma Co., Ltd.
  • Daiichi Sankyo RD Novare Co., Ltd.
  • Daiichi Sankyo Biotech Co. Ltd.
  • Astellas Pharma, Inc. /3 Drug Products/
  • Daiichi Sankyo Belgium SA
  • Daiichi Sankyo Restricted Stock Compensation Plan
  • Daiichi Sankyo Pharma, Inc.
  • Novare Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.
  • Daiichi Sankyo Venezuela SA
  • Daiichi Sankyo (Schweiz) AG
  • Daiichi Sankyo Hong Kong Ltd.
  • Daiichi Forging Dalian Co. Ltd.
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • Daiichi Sankyo Pension Fund
  • Daiichi Sankyo Espha Co., Ltd.
  • Daiichi Sankyo (Thailand) Ltd.
  • Daiichi Sankyo Employee Stock Ownership Plan
  • Daiichi Sankyo (China) Holdings Co., Ltd.
  • Daiichi Sankyo Ireland Ltd.
  • Sankyo Pharma Nederland BV
  • Daiichi Sankyo Taiwan Ltd.
  • NV Sankyo Pharma Belgium SA
  • Daiichi Sankyo Portugal, Unipessoal, Lda.
  • Daiichi Sankyo Austria GmbH
  • Daiichi Sankyo Nederland BV
  • Daiichi Sankyo Logistics Co. Ltd.
  • Daiichi Sankyo Italia SpA
  • U3 Pharma GmbH
  • Daiichi Sankyo Deutschland GmbH


  • AstraZeneca PLC
  • Boryung Corporation
  • Hanmi Pharmaceutical Co., Ltd.
  • LegoChem Biosciences, Inc.
  • ImmunoGen, Inc.
  • Zymeworks Inc.
  • Zymeworks Inc.
  • Biomea Fusion Inc
  • NeuroBo Pharmaceuticals, Inc.
  • Aprea Therapeutics, Inc.
  • Springworks Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • IGM Biosciences, Inc.
  • Sutro Biopharma, Inc.
  • Bolt Biotherapeutics, Inc.
  • Reata Pharmaceuticals, Inc. Class A
  • Aileron Therapeutics, Inc.
  • Ambrx Biopharma, Inc. Sponsored ADR
  • CytomX Therapeutics, Inc.
  • Oncorus, Inc.
  • Blueprint Medicines Corp.
  • MacroGenics, Inc.
  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A
  • ADC Therapeutics Ltd
  • PTC Therapeutics, Inc.
  • Nuvation Bio, Inc. Class A
  • Defence Therapeutics Inc Class A
  • Iovance Biotherapeutics Inc
  • Janux Therapeutics, Inc.
Last Updated on 9 Jun, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more